Filing Flows › Prestige Consumer Healthcare (PBH) › Guidance & outlook
Prestige Consumer Healthcare (PBH) guidance and outlook
Prestige Consumer Healthcare (PBH) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $1.3B for FY2027; EPS $4.48–$4.55 for FY2027; Revenue +8% for FY2027; Revenue $1.3B for FY2027. Prestige Consumer Healthcare's 10-Q filed Nov 5, 2026 makes 7 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2027 | $1.3B | lowered |
| EPS | FY2027 | $4.48–$4.55 | lowered |
| Revenue | FY2027 | +8% | raised |
| Revenue | FY2027 | $1.3B | raised |
| Free cash flow | FY2027 | $270M | raised |
| Operating cash flow | FY2027 | $269M | new |
| Free cash flow | FY2027 | $265M | new |
| EPS | FY2027 | $3.53 | lowered |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products.
- Recently, all of our sterile eye care manufacturing sites, including those operated by certain third-party manufacturers, have undergone inspections by health authorities, and we and our third-party manufacturers are actively engaging with those authorities and implementing responsive actions intended to strengthen quality systems, improve production consistency and support more reliable supply over time.
- We believe these ongoing investments and engagement with health authorities will better position us and our third-party manufacturers to improve supply reliability and support recovery in affected product categories over the long-term.
- This legislation has not and is not expected to have a material impact on our Consolidated Financial Statements.
- We have financed our operations, and expect to continue to finance our operations for the next twelve months and the foreseeable future, with a combination of funds generated from operations and borrowings.
- Based on our current levels of operations and anticipated growth, excluding acquisitions, we believe that our cash generated from operations and our existing credit facilities will be adequate to finance our working capital and capital expenditures through the next twelve months.
- Management anticipates that in the normal course of operations, we will be in compliance with the applicable covenants during the next twelve months.
Prestige Consumer Healthcare's latest quarter
Prestige Consumer Healthcare, Q2 FY27: revenue $336M (+23% year over year), operating margin 24.0%, net earnings $25.3M, operating cash flow $37.9M. The chart follows the revenue to costs, profit and cash.
Questions
Did Prestige Consumer Healthcare raise or lower its guidance?
Prestige Consumer Healthcare (PBH) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $1.3B for FY2027; EPS $4.48–$4.55 for FY2027; Revenue +8% for FY2027; Revenue $1.3B for FY2027.
What does Prestige Consumer Healthcare expect?
We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. Recently, all of our sterile eye care manufacturing sites, including those operated by certain third-party manufacturers, have undergone inspections by health authorities, and we and our third-party manufacturers are actively engaging with those authorities and implementing responsive actions intended to strengthen quality systems, improve production consistency and support more reliable supply over time. We believe these ongoing investme
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.